Oct 06, 2022

The only EGFR-tyrosine kinase inhibitor presently authorized for advanced non-small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I is afatinib. However, afatinib's advantages and resist...

Oct 06, 2022

The utility of sputum cell-free DNA (cfDNA) as a surrogate material for detecting EGFR mutations in lung adenocarcinoma (LAC) patients has been shown. However, it has not been documented if it is appr...

Oct 06, 2022

When non-small cell lung cancer (NSCLC) patients were first diagnosed, metastases were common. On the other hand, little was known about the variables that contribute to its metastasis. For a study, r...

Oct 06, 2022

Patients with hematologic malignancies have had encouraging outcomes using T-cell-recruiting bispecific molecule treatment, although resistance and subsequent recurrence remain significant obstacles. ...

Oct 05, 2022

Autoantibody production or abnormalities in the genes that code for coagulation factors may result in coagulation disorders that pose substantial hazards for bleeding. As has been well-documented in t...

Oct 05, 2022

MONDAY, Oct. 3, 2022 (HealthDay News) -- An electronic alert-triggered, patient-centered education bundle intervention or a nurse feedback intervention can improve administration of venous thromboembo...

Oct 05, 2022

MONDAY, Oct. 3, 2022 (HealthDay News) -- In a clinical report issued by the American Academy of Pediatrics and published online Sept. 19 in Pediatrics, recommendations are presented to help guide pedi...

Oct 05, 2022

MONDAY, Oct. 3, 2022 (HealthDay News) -- For early-stage invasive breast cancer, involved or close pathological margins after breast-conserving surgery are associated with an increased risk for distan...

Oct 05, 2022

MONDAY, Oct. 3, 2022 (HealthDay News) -- For a sample of 60 drugs, research and development investments do not explain the variation in list prices, according to a study published online Sept. 26 in J...

Oct 05, 2022

TUESDAY, Oct. 4, 2022 (HealthDay News) -- Medicare eligibility and enrollment at age 65 years is associated with improvements in some measures of health care access and affordability, according to a s...

Oct 05, 2022

The heterogeneous T-cell neoplasm known as peripheral T-cell lymphomas (PTCLs) is frequently linked to epigenetic instability. For a study, researchers sought to determine novel molecular subtypes of ...

Oct 05, 2022

When exposed to ambient air compared to physioxia, hematopoietic stem cells (HSCs) exhibit decreased recovery and self-renewal with a concurrent increase in differentiation. Although the mechanism(s) ...

Oct 05, 2022

There wasn't enough proof to support the preventive use of tranexamic acid (TXA) in thrombocytopenia. A randomized, double-blind clinical trial was carried out from June 2016 to June 2020 to find out ...

Oct 05, 2022

Androgen axis modulators, PARP inhibitors, and PSMA theranostics have all been demonstrated to increase overall survival in men with metastatic castrate-resistant prostate cancer. Clinically localized...

Oct 05, 2022

Patients with metastatic castrate-sensitive prostate cancer (mCSPC) must deal with pain as a significant aspect of their quality of life. It was unknown, nevertheless, whether a dynamic change in pain...

Oct 05, 2022

Researchers had previously demonstrated the potential validity of radiographic progression-free survival as a proxy for overall survival. For a study, they sought to investigate the validity of time t...

Oct 05, 2022

For patients with mCSPC, the current standard of treatment is to intensify androgen deprivation therapy (ADT) with docetaxel or androgen receptor axis-targeted therapy (ARAT: abiraterone, apalutamide,...

Oct 05, 2022

When added to the protocol-allowed standard of care (SoC) in patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer, lutetium (177Lu) vipivotide tetraxetan ([177Lu]Lu...

Oct 05, 2022

ADT + DOC was adopted as the norm for care in MHSPC. Clinical studies CHAARTED and STAMPEDE combined 6 cycles of DOC with ADT for induction, whereas GETUG-AFU-15 employed 9 cycles of DOC. Early DOC us...

Oct 05, 2022

Patients were enrolled in PROpel regardless of the presence of HRR gene mutations (HRRm). The radiographic progression-free survival by HRRm status and HRRm determination, however, were predetermined ...